52,810 Shares in Grifols, S.A. (NASDAQ:GRFS) Bought by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC purchased a new stake in shares of Grifols, S.A. (NASDAQ:GRFSFree Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 52,810 shares of the biotechnology company’s stock, valued at approximately $610,000.

Several other large investors have also recently modified their holdings of GRFS. Brandes Investment Partners LP grew its position in Grifols by 22.2% during the 4th quarter. Brandes Investment Partners LP now owns 13,516,011 shares of the biotechnology company’s stock worth $156,245,000 after acquiring an additional 2,454,730 shares during the last quarter. Black Creek Investment Management Inc. grew its holdings in Grifols by 16.4% in the 3rd quarter. Black Creek Investment Management Inc. now owns 9,574,388 shares of the biotechnology company’s stock worth $87,510,000 after acquiring an additional 1,351,000 shares during the last quarter. Norges Bank purchased a new position in shares of Grifols in the fourth quarter valued at about $26,137,000. New York State Common Retirement Fund raised its stake in shares of Grifols by 38.5% during the fourth quarter. New York State Common Retirement Fund now owns 2,058,286 shares of the biotechnology company’s stock valued at $23,794,000 after acquiring an additional 572,439 shares during the last quarter. Finally, Sei Investments Co. boosted its holdings in shares of Grifols by 185.4% during the third quarter. Sei Investments Co. now owns 2,002,818 shares of the biotechnology company’s stock worth $18,306,000 after purchasing an additional 1,300,978 shares during the period.

Grifols Trading Down 3.6 %

NASDAQ:GRFS opened at $7.24 on Friday. The company has a current ratio of 2.79, a quick ratio of 1.29 and a debt-to-equity ratio of 1.26. The firm’s fifty day simple moving average is $6.96 and its 200 day simple moving average is $8.00. Grifols, S.A. has a twelve month low of $5.30 and a twelve month high of $12.15.

Analyst Ratings Changes

Separately, Deutsche Bank Aktiengesellschaft downgraded Grifols from a “hold” rating to a “sell” rating in a report on Tuesday, March 12th.

Read Our Latest Analysis on Grifols

Grifols Company Profile

(Free Report)

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

See Also

Institutional Ownership by Quarter for Grifols (NASDAQ:GRFS)

Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.